



1/5

SEQUENCE LISTING

<110> Francis P. Tally
Jianshi Tao
Philip A. Wendler
Gene Connelly
Paul L. Gallant

<120> METHOD FOR IDENTIFYING VALIDATED TARGET
AND ASSAY COMBINATIONS FOR DRUG DEVELOPMENT

<130> CPI98-03p9MA

<140> US 09/227,687

<141> 1999-01-08

<150> US 60/070965

<151> 1998-01-09

<150> US 60/076,688

<151> 1998-03-03

<150> US 60/081,753

<151> 1998-04-14

<150> US 60/085,844

<151> 1998-05-18

<150> US 60/089,828

<151> 1998-06-19

<150> US 60/094,698

<151> 1998-07-30

<150> US 60/100,211

<151> 1998-09-14

<150> US 60/101,718

<151> 1998-09-24

<150> US 60/107,751

<151> 1998-11-10

<160> 17

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 15

<212> PRT

<213> Artificial Sequence

Sub
A1

<220>

<223> Peptide

<400> 1

Ser Arg Asp Trp Gly Phe Trp Asp Trp Gly Val Asp Arg Ser Arg
 1 5 10 15

<210> 2

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide

<400> 2

Ser Arg Asp Trp Gly Phe Trp Arg Leu Pro Glu Ser Met Ala Ser Arg
 1 5 10 15

<210> 3

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide

<400> 3

Ser Arg Glu Trp His Phe Trp Arg Asp Tyr Asn Pro Thr Ser Arg
 1 5 10 15

<210> 4

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide

<400> 4

Ser Ser Glu Arg Gly Ser Gly Asp Arg Gly Glu Lys Gly Ser Arg
 1 5 10 15

<210> 5

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5

ccaacaacat atgtcccgtg aatggcactt ctggcgtgac tac

<210> 6
 <211> 57
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 6
 ttctggcgtg actacaacc gacctcccg t ggggggtggag gcatgtcccc tatacta 57

<210> 7
 <211> 32
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 7
 agttgaattc ttaatccgat ttggaggat gg 32

<210> 8
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 8
 caaggtaccc atgtcccgtg aatggcac 28

<210> 9
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 9
 cgcggatcct taatccgatt ttggaggatg g 31

<210> 10
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 10
 aatccgctcg aggattattg ctattgggtgc c 31

Sub
a'
cont

<210> 11
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 11
 aatcgtaagc ttttatttta agttatcata ttt

33

<210> 12
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide

<400> 12
 Asp Pro Asn Thr Trp Gln Leu Arg Trp Pro Met His
 1 5 10

<210> 13
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide

<400> 13
 Met Trp Asp Leu Pro Tyr Ile Trp Ser Arg Pro Val
 1 5 10

<210> 14
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide

<400> 14
 Ala Asp Thr Leu Asn Trp Tyr Tyr Tyr Ala Ser Trp
 1 5 10

<210> 15
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide

Sub
 at
 cont

<400> 15
 Ala Asn Asn Leu Ser Thr Met Lys Lys Leu Lys Gln
 1 5 10

<210> 16
 <211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide

<400> 16
 Ser Arg Glu Trp His Phe Trp Arg Asp Tyr Asn Pro Thr Ser Arg Gly
 1 5 10 15
 Gly Lys Phe Ile Thr Cys
 20

<210> 17
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide

<400> 17
 Asp Pro Asn Thr Trp Gln Leu Arg Trp Pro Met His Gly Gly Lys Phe
 1 5 10 15
 Ile Thr Cys

Sub
 at
 cent